

FORM PTO-1 (Rev. 7-11-2001) (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 61646 (70904)
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <div style="font-size: 1.5em; font-weight: bold; text-align: center;">10/501259</div>
INTERNATIONAL APPLICATION NO. PCT/JP03/00089	INTERNATIONAL FILING DATE January 8, 2003	PRIORITY DATE CLAIMED January 11, 2002
TITLE OF INVENTION DISEASE SUSCEPTIBILITY GENE FOR RHEUMATOID ARTHRITIS, PROTEIN THEREOF, EVALUATION METHOD AND EVALUATION KIT FOR EVALUATING ONSET POSSIBILITY OF RHEUMATOID...		
APPLICANT(S) FOR DO/EO/US Shunichi SHIOZAWA, Koichiro KOMAI, and Mikiko NAKATSUKASA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 		
Items 13 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Express Mail Label No. <u>EV 437 819 430 US</u> 23. <input checked="" type="checkbox"/> Other items or information: 		
Paper copy of Sequence Listing (8 pages); Copy of PCT Request (Form PCT/RO/101); Copy of Form PCT/IB/304; Copy of Form PCT/IB/308; Certificate of Express Mailing; and return postcard.		

107501259	INTERNATIONAL APPLICATION NO. PCT/JP03/00089	ATTORNEY'S DOCKET NUMBER 61646 (70904)
-----------	---	---

24. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1080.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$770.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$920.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	13 - 20 =	0	x \$18.00	\$0.00	
Independent claims	3 - 3 =	0	x \$86.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/>	\$290.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,210.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,210.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,210.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input checked="" type="checkbox"/>	\$40.00	
TOTAL FEES ENCLOSED =				\$1,250.00	
				Amount to be: refunded	\$
				charged	\$

- a. ☒ A check in the amount of \$1,250.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
- c. ☒ The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1105
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin, Reg. No. 27,026
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Tel.: (617)439-4444

SIGNATURE

Jennifer K. Rosenfield

NAME

53,531

REGISTRATION NUMBER

July 9, 2004

DATE

10/501259

NT04 Rec'd PCT/PTO 09 JUL 2004

Attorney's Docket No. 61646 (70904)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SHIOZAWA, Shunichi et al.

U.S.S.N.: Not yet Assigned

Examiner: Not Yet Assigned

Filed: Herewith

Group: Not Yet Assigned

For: DISEASE SUSCEPTIBILITY GENE FOR RHEUMATOID ARTHRITIS, PROTEIN THEREOF, EVALUATION METHOD AND EVALUATION KIT FOR EVALUATING ONSET POSSIBILITY OF RHEUMATOID ARTHRITIS BY USING THOSE, AND REMEDY AND CURING MEDICINE FOR RHEUMATOID ARTHRITIS

Mail Stop: PCT

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450


CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. 1.10

I hereby certify that the attached correspondence comprising:

US National Stage (35 U.S.C. 371) Filing of International Application PCT/JP03/00089, including:

1. Transmittal Letter (2 pages);
2. Copy of the published application - International Publication No. WO 03/060126 A1 (44 pages);
3. English translation of the application as filed (34 pages of specification, 4 pages of claims, 1 page of abstract, 4 sheets of drawings, and 8 pages of sequence listing);
4. Executed Declaration and Power of Attorney (4 pages);
5. Copy of the International Preliminary Examination Report (Form PCT/IPEA/409) (5 pages);
6. Copy of the International Search Report (Form PCT/ISA/210) (4 pages);
7. Copy of the PCT Request (Form PCT/RO/101) (5 pages);
8. Copy of Form PCT/IB/304 (1 page);
9. Copy of Form PCT/IB/308 (1 page)
10. Recordation Form Cover Sheet (1 page);
11. True copy of Executed Assignment to Shunichi SHIOZAWA (2 pages); and
12. Check in the amount of \$1250.00 to cover filing fees and assignment recordation;

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 (Express Mail Label No. EV 437 819 430 US), and is addressed to: Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 9, 2004.


Sharon Bizokas